Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers

Adi, Handoko; Young, Paul M.; Traini, Daniela

doi:10.1111/j.2042-7158.2011.01370.x

Cited by 13 publications

(5 citation statements)

References 47 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean in vitro lung doses per actuation as measured on the filters at each altitude are listed in Table . The in vitro lung doses were close to reported fine particle doses for inhalers with high performance, that is, 90–100 μg for the budesonide component of Symbicort ® , or slightly larger than the reported fine particle doses for Ventolin ® and Airomir™, as expected. The in vitro lung dose for QVar ® agreed with previously reported mouth–throat deposition using the Alberta Idealized Throat …”

Section: Resultssupporting

confidence: 81%

The Effect of Altitude on Inhaler Performance

Titosky

Morin

Suderman

et al. 2014

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Section: Resultssupporting

confidence: 81%

The Effect of Altitude on Inhaler Performance

Titosky

Morin

Suderman

et al. 2014

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…The recent approval of tiotropium–olodaterol SMI 62 illustrates that demand for combination therapy is driving device innovation. Cosuspension-based pMDIs, for example, are in development, 89 , 91 , 92 which may facilitate further innovation in fixed-dose combination inhaler products. For example, the US Federal Drug Administration recently approved a novel LAMA/LABA cosuspension-based pMDI (glycopyrrolate and formoterol fumarate) for patients with COPD.…”

Section: Discussionmentioning

confidence: 99%

A review of nebulized drug delivery in COPD

Tashkin¹

2016

COPD

View full text Add to dashboard Cite

Current guidelines recommend inhaled pharmacologic therapy as the preferred route of administration for treating COPD. Bronchodilators (β2-agonists and antimuscarinics) are the mainstay of pharmacologic therapy in patients with COPD, with long-acting agents recommended for patients with moderate to severe symptoms or those who are at a higher risk for COPD exacerbations. Dry powder inhalers and pressurized metered dose inhalers are the most commonly used drug delivery devices, but they may be inadequate in various clinical scenarios (eg, the elderly, the cognitively impaired, and hospitalized patients). As more drugs become available in solution formulations, patients with COPD and their caregivers are becoming increasingly satisfied with nebulized drug delivery, which provides benefits similar to drugs delivered by handheld inhalers in both symptom relief and improved quality of life. This article reviews recent innovations in nebulized drug delivery and the important role of nebulized therapy in the treatment of COPD.

show abstract

“…Finally, two or three of the drugs can be formulated in an HFA system as a solution formulation. To formulate ipratropium, formoterol, and budesonide in HFA, the drugs were dissolved in the system using ethanol (161). The resulting formulation delivered 5 μg ipratropium bromide, 2.25 μg fomoterol fumarate, and 80 μg budesonide.…”

Section: Combination Drug MDI Productsmentioning

confidence: 99%

Advances in Metered Dose Inhaler Technology: Formulation Development

2014

View full text Add to dashboard Cite

Pressurized metered dose inhalers (MDIs) are a long-standing method to treat diseases of the lung, such as asthma and chronic obstructive pulmonary disease. MDIs rely on the driving force of the propellant, which comprises the bulk of the MDI formulation, to atomize droplets containing drug and excipients, which ideally should deposit in the lungs. During the phase out of chlorofluorocarbon propellants and the introduction of more environmentally friendly hydrofluoroalkane propellants, many improvements were made to the methods of formulating for MDI drug delivery along with a greater understanding of formulation variables on product performance. This review presents a survey of challenges associated with formulating MDIs as solution or suspension products with one or more drugs, while considering the physicochemical properties of various excipients and how the addition of these excipients may impact overall product performance of the MDI. Propellants, volatile and nonvolatile cosolvents, surfactants, polymers, suspension stabilizers, and bulking agents are among the variety of excipients discussed in this review article. Furthermore, other formulation approaches, such as engineered excipient and drug-excipient particles, to deliver multiple drugs from a single MDI are also evaluated.

show abstract

Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers

Abstract: This study demonstrated the feasibility of formulating a solution-based pMDI containing a triple therapy with identical deposition pattern for the treatment of several respiratory diseases where multi-drug cell targeting is required.

Cited by 13 publications

References 47 publications

The Effect of Altitude on Inhaler Performance

The Effect of Altitude on Inhaler Performance

A review of nebulized drug delivery in COPD

Advances in Metered Dose Inhaler Technology: Formulation Development

Contact Info

Product

Resources

About